Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b Dose Finding Study of BMF-219, an Oral Covalent Menin Inhibitor, in Adult Patients With Unresectable, Locally Advanced, or Metastatic Non-small Cell Lung Cancer (NSCLC), Pancreatic Cancer (PDAC), and Colorectal Cancer (CRC)

NCT05631574 is registered in ClinicalTrials.gov with Biomea Fusion Inc. as lead sponsor.

NCT NCT05631574
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05631574 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b Dose Finding Study of BMF-219, an Oral Covalent Menin Inhibitor, in Adult Patients With Unresectable, Locally Advanced, or Metastatic Non-small Cell Lung Cancer (NSCLC), Pancreatic Cancer (PDAC), and Colorectal Cancer (CRC)
Lead sponsor
Biomea Fusion Inc.
Phase
Phase 1
Overall status
Terminated
Start date
January 12, 2023
Completion date
January 15, 2025
Enrollment
13 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, crc, kras mutation-related tumors, non small cell lung cancer, nsclc, pancreatic cancer, pdac, refractory cancer, relapsed cancer, stage iii colorectal cancer, stage iii non-small cell lung cancer, stage iii nsclc, stage iii pancreatic cancer, stage iv colorectal cancer, stage iv non-small cell lung cancer, stage iv nsclc, stage iv pancreatic cancer